BCG-WEF Project: Digital Health Care Transformation

The System Is Not the Patient: Next Steps for Implementing Outcome-Based Care

Health care systems around the globe face considerable pressures. Rising demand driven by ageing populations and chronic disease, combined with constrained resources and workforce shortages, is exposing a fundamental mismatch between health expenditure and outcomes. At the same time, a significant share of care continues to deliver limited value, and care delivery remains insufficiently aligned with what matters most to patients. Together, these pressures are shifting the central challenge in health care from expanding activity to improving the value of the care delivered.

Outcome-based care offers a clear strategic direction by redefining success in terms of patient population outcomes relative to resources used. While its conceptual foundations are well established and a growing number of real-world examples demonstrate feasibility, implementation remains fragmented. Most initiatives are confined to specific conditions or settings and have not yet translated into system-wide transformation or cascaded into a health system that continually evaluates the outcomes achieved through the care delivered. Commonly cited barriers—such as the need for full system redesign, fully aligned incentives, and perfect measurement systems—continue to slow progress, despite increasing evidence that these are not prerequisites for action.

Drawing on insights from global expert discussions, the World Economic Forum and BCG argue that scaling outcome-based care does not necessitate full-system redesign but can begin through six interdependent, practical shifts that organizations can make immediately:

• Establishing clinically meaningful, standardized outcomes
• Reorganizing care around patient pathways rather than individual episodes
• Progressively aligning incentives with outcomes
• Building the community infrastructure and cross-sector partnerships necessary to address the social drivers of health
• Enabling expansion through interoperable digital and data infrastructure
• Promoting the behaviors, capabilities, and culture required to translate these changes into everyday clinical practice

These shifts are mutually reinforcing and can be advanced incrementally to build evidence, trust, and momentum over time. The implication for leaders is clear: the challenge is no longer defining what outcome-based care should look like but executing it in practice. Many of the necessary building blocks already exist yet remain fragmented across systems and among stakeholders. Progress will depend on aligning measurement practices, incentives, care delivery, and digital capabilities while enabling front-line teams and patients to act on outcomes data.

Outcome-based care is not an abstract aspiration but a pathway to achieve what matters to patients, reducing low-value care and ensuring the long-term sustainability of health systems.

Strategic Choices in the Age of AI: Shaping the Future of Life Sciences

AI and increasingly connected data ecosystems are reconfiguring the life sciences value chain, with implications for how innovation is generated, translated, and delivered to patients. While digital technologies have already raised the industry’s performance baseline, AI is shifting the focus from optimizing the current value chain to redefining its structure, thereby expanding the range of viable strategic positions and forcing more explicit choices about where and how companies compete.

Competitive advantage is no longer anchored in incremental improvements but in how organizations position themselves within a fundamentally evolving system.

Analysis by the World Economic Forum and BCG identifies two fundamental shifts. First, in R&D, AI removes scarcity in research by dramatically increasing the volume and speed of hypothesis generation. As a result, the bottleneck shifts downstream, from discovery to development, translation, and evidence generation. Competitive advantage increasingly depends on the ability to convert a larger share of ideas into approved, adopted, and scalable interventions, supported by continuous learning systems that integrate clinical and real-world data.

Second, in market access and distribution, AI and digital interfaces reshape how demand is formed, how decisions are influenced, and how products reach patients. Multiple access pathways are emerging in parallel (provider-led, direct-to-patient, and new intermediary-driven models), each requiring distinct capabilities, operating models, and economic logic.

Across these shifts, three strategic approaches emerge in both R&D and commercialization. In R&D, companies may position themselves as AI-supported science champions, asset integrators, or development engines. In access and distribution, they may reinforce provider-led pathways, build direct patient relationships, or challenge traditional distribution models. These approaches are not mutually exclusive, but pursuing all simultaneously risks strategic dilution. Leaders must therefore make deliberate choices and align capabilities, organization and investment accordingly.

The WEF-BCG analysis has two immediate implications. First, organizations must move beyond isolated digital initiatives and build integrated, life cycle–spanning capabilities, supported by interoperable data and embedded across core processes. Second, leaders must make explicit choices about where and how to compete within a reconfigured value chain. Incremental adaptation is no longer sufficient; sustained advantage requires aligning capabilities, operating models, and investment around a clear strategic position.

Looking ahead, the pace and direction of transformation will depend on alignment between industry and the public sector. Regulatory frameworks, reimbursement models, and data governance will shape which approaches can scale and where capabilities concentrate.

As AI reshapes both the creation and delivery of innovation, life sciences companies must transition from optimizing existing models to building fundamentally new ones, defining how value is created, captured, and sustained in the decades ahead.

Earning Trust for AI in Health: A Collaborative Path Forward

Health care systems globally face growing pressures: rising costs, workforce shortages, and persistent inefficiencies. In this context, AI offers transformative opportunities to enhance patient outcomes and optimize system performance. But realizing AI’s benefits in health care requires responsible development, rigorous evaluation, and a deliberate focus on building trust among stakeholders.

Today’s regulatory frameworks, designed primarily for pharmaceuticals and medical devices, are not fully suited to manage the probabilistic, dynamic nature of AI technologies. Traditional evaluation methods, which emphasize pre-market validation, struggle to accommodate AI systems that evolve post-deployment. As AI adoption accelerates, regulatory models must evolve accordingly.

New research from the World Economic Forum and BCG identifies three urgent priorities to earn trust for AI in health:

Address fragmentation and build technical capacity. Current AI ecosystems are fragmented, and many health leaders lack a deep understanding of AI technologies. Health systems must build technical literacy among decision makers so that they can critically assess and responsibly integrate AI solutions.

Adapt evaluation and regulatory frameworks. New approaches, such as regulatory sandboxes, post-market surveillance, and life-cycle monitoring are essential. Guidelines must complement legislation to enable innovation while maintaining high standards of safety and effectiveness. Independent quality assurance resources and real-world testing environments, such as those being developed under initiatives like the Testing and Experimentation Facility for Health AI and Robotics (TEF-Health), can support more dynamic development.

Promote public–private collaboration. Public–private partnerships should move beyond consultation to active codevelopment of evaluation standards and monitoring frameworks. Such collaboration is vital to ensure that regulatory practices keep pace with AI innovation while safeguarding patient trust and public health objectives.

The WEF-BCG research also emphasizes the importance of global coordination. Divergences in AI regulatory approaches across regions—especially between the Global North and Global South—risk creating barriers to the scalable deployment of AI in health care. Capacity-building efforts, particularly in underresourced health systems, are crucial to ensure equitable benefits from AI advances.

Ultimately, the future of AI in health care must be grounded in adaptability, transparency, and shared responsibility. By strengthening evaluation processes, building technical capacity, and fostering structured public–private collaboration, health systems can unlock the transformative potential of AI while upholding patient safety and trust and ensuring broader access to innovation.

The path forward demands continuous innovation not only in technology but also in regulation and system design. The time to act is now, to ensure that AI fulfils its promise of delivering better health outcomes for all.